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Abstract
Background Only limited data exist on the clinical utility
of remote magnetic navigation (RMN) for pulmonary vein
(PV) ablation. Aim of this prospective study was to eval-
uate the safety and efﬁcacy of RMN for PV isolation as
compared to the manual (CON) approach.
Methods and results A total of 161 consecutive patients
undergoing circumferential PV isolation were included.
Open-irrigated 3.5 mm ablation catheters under the guid-
ance of a mapping system were used. The catheter was
navigated with the Stereotaxis Niobe II system in the RMN
group (n = 107) and guided manually in the CON group
(n = 54). Electrical isolation of all PVs was achieved in
90% of the patients in the RMN group and in 87% in the
CON group (p = 0.6). All subjects were followed every
3 months by 7d Holter-ECG. At 12 months of follow-up,
53.5% (RMN) and 55.5% (CON) of the patients were free
of any left atrial tachycardia/atrial ﬁbrillation (AF) episode
(p = 0.57). Free of symptomatic AF recurrence were
66.3% (RMN) and 62.1% (CON) of the subjects
(p = 0.80). Use of RMN was associated with longer pro-
cedure duration (p\0.0001), ablation times (p\0.0001),
and RF current application duration (p\0.05). In contrast,
ﬂuoroscopy time was lower in the RMN group
(p\0.0001). Major complications occurred in 6 of 161
procedures (3.7%), with no signiﬁcant difference between
groups (p = 0.75).
Conclusion RMN-guided PV ablation provides compa-
rable acute and long-term success rates as compared to
manual navigation. Procedural complication rates are
similar. The use of RMN is associated with markedly
reduced ﬂuoroscopy time, but prolonged ablation and
procedure duration.
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Introduction
In the past years, ablation strategies to isolate the pul-
monary veins have become an established treatment choice
for patients with drug-refractory symptomatic atrial ﬁbril-
lation (AF) [1]. Navigating the catheter safely within the
left atrium to produce effective ablation lesions at all
desired locations can prove to be challenging even for the
skilled electrophysiologist. Long-term success rates of the
procedure, deﬁned by freedom from AF during follow-up,
range between 60 and 80% [2], whereas severe complica-
tions may occur in up to 4.5% of the cases [3]. Stiff
ablation catheters mandate frequent visualization of the
catheter tip during manipulation, therefore, procedure
related radiation exposure may be extensive to patient and
operator [4]. Efforts continue to improve the safety and
efﬁcacy of this widely applied procedure.
Recently, a magnetic catheter navigation system (Niobe
II, Stereotaxis Inc., St. Louis, MO, USA) for remote
mapping and ablation of cardiac arrhythmias has been
introduced. Potential beneﬁts of this system comprise a
reduction of radiation exposure as well as improved pro-
cedural safety and efﬁcacy due to an unrestricted and more
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limited data are available on the exact clinical utility of the
remote magnetic catheter navigation (RMN) system for
pulmonary vein (PV) isolation and treatment of AF [5–10].
The aim of this prospective observational study was to
evaluate the safety and efﬁcacy of the RMN-system for PV
isolation and treatment of AF as compared to a conven-
tional manual approach.
Methods
Patient selection
Consecutive patients undergoing circumferential PV iso-
lation at our centre between April 2008 and April 2010
were included in this study. All patients had conventional
indications with symptomatic AF and a failed attempt to
maintain sinus rhythm with antiarrhythmic medication [1].
Conventional manual AF ablation was introduced at our
center in 2006. The RMN-system was utilized for all AF
ablation procedures beginning November 2008. The con-
trol group consisted of those 54 consecutive patients that
underwent conventional manual ablation (CON) between
April and October 2008 (before switching to RMN-guided
ablation).
Exclusion criteria were hyperthyroidism, LA thrombus,
decompensated heart failure, stroke, myocardial infarction
or gastrointestinal bleeding within 4 weeks prior to the
intervention, and life-expectancy\6 months.
Electrophysiological study
In all subjects, left atrial (LA) thrombi were excluded by
transesophageal echocardiography, and LA anatomy was
acquired by high-resolution thoracic computer tomography
imaging just prior to the procedure. All ablation procedures
were performed during conscious sedation using intrave-
nous sufentanil, midazolam and/or propofol under contin-
uous monitoring of blood pressure and oxygen saturation.
For the electrophysiological procedure, all catheters
were advanced via the femoral vein. A 6F steerable deca-
polar catheter (Bard Dynamic Tip, Bard Inc., Lowell, MA,
USA) was positioned in the coronary sinus. After a ﬂuo-
roscopically guided transseptal puncture an SL1 sheath (St.
Jude Medical, Inc., St. Paul, MN, USA) in the RMN group
or an Agilis deﬂectable sheath (St Jude Medical) in the
CON group were advanced into the LA. Intravenous hep-
arin was administered immediately after the transseptal
puncture to maintain an activated clotting time of
250–300 s throughout the procedure. In the RMN group, a
3.5 mm open-irrigated, magnetic mapping and ablation
catheter (Navistar Thermocool RMT, Biosense Webster,
Diamond Bar, USA) was advanced through the sheath into
the LA, whereas in the CON group a manually guided
3.5 mm open-irrigated mapping and ablation catheter
(Navistar Thermocool, Biosense Webster) was used.
Patients presenting with sustained atrial ﬁbrillation under-
went electrical cardioversion for mapping and ablation.
Circumferential pulmonary vein ablation was performed
using a three-dimensional mapping system (CartoMerge
XP, Biosense Webster) in conjunction with the integrated
CT image of the LA and real-time ﬂuoroscopy. In the RMN
group, the Niobe II magnetic navigation system (Stereo-
taxis) and a joystick-controlled motor drive (Cardiodrive,
Stereotaxis) were utilized for remote magnetic navigation
of the ablation catheter, whereas in the CON group the
ablation catheter was guided manually.
The RMN system has been described in detail elsewhere
[10]. Brieﬂy, two permanent magnets located on either side
of the procedure desk generate a magnetic ﬁeld (0.08
Tesla) within the patient. The magnetic ablation catheter
incorporates four magnets in the distal portion of the
catheter. A change of the desired vector for catheter ori-
entation on a computer screen results in alteration of the
magnetic ﬁeld generated by the permanent magnets and
thereby corresponding deﬂection of the magnetic catheter
within the heart. The joystick-controlled motor drive
allows catheter advancement and retraction. Thus, the
system provides complete remote catheter navigation for
mapping and ablation.
The radiofrequency (RF) generator (Stockert, Biosense
Webster) was set to temperature controlled RF delivery
with a target temperature of 45C and a nominal power
limit of 40 W (ﬂow 30 ml/min) and 30 W (ﬂow 17 ml/
min) at the posterior LA wall. RF current was applied for
30–60 s until local electrogram amplitude was reduced by
80%. Endpoint of the ablation procedure was the electrical
isolation of all PVs deﬁned as bidirectional conduction
block. This was veriﬁed by careful and repeated mapping
for residual potentials around the entire circumference of
the PV ostia, and pacing from multiple sites within the
circumferential line.
Follow-up
All patients were monitored in the hospital at least over-
night. Echocardiography was performed within 24 h after
the procedure and in cases of unexplained hypotension to
rule out pericardial effusion. On the day after the proce-
dure, the venous puncture site was inspected for signiﬁcant
local hemorrhage, and a 12-lead surface ECG was acquired
to conﬁrm normal sinus rhythm. Antiarrhythmic medica-
tion was administered according to the investigators dis-
cretion. Oral anticoagulation was restarted the day after the
procedure with a target INR of 2.0–3.0. Bridging with
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ated 6–12 h after the procedure. After hospital discharge,
all patients were followed in our outpatient clinic every
3 months for at least 1 year. At each visit, subjects were
asked for symptoms, documented arrhythmia recurrences,
and current medication was assessed. Ambulatory holter
monitoring was performed for 7 days at each follow-up to
reveal possible arrhythmia recurrences. Furthermore, all
patients were advised to present immediately in case of
symptoms suggestive for arrhythmia recurrence and obtain
ECG documentation. A documented AF or left atrial
tachycardia (AT) episode lasting longer than 30 s outside a
blanking period of 2 months after the index procedure were
considered as recurrent AT/AF. Additional diagnostic
information (e.g., echocardiogram, chest X-ray/computer-
tomography) was acquired if symptoms were suggestive of
procedure-related complications (e.g., pericardial effusion,
pulmonary vein stenosis).
Study endpoints
The primary endpoint of this prospective observational
study was acute procedural success, deﬁned as the number
of PVs isolated at the end of the procedure. Secondary
endpoints were long-term procedural success, deﬁned as
long-term freedom from any AT/AF episodes irrespective
of symptoms after the index procedure during 12 months
of follow-up, and survival without symptomatic AF
recurrence after the index procedure during 12 months of
follow-up. Further secondary endpoints were freedom
from symptomatic AF recurrence at the end of the indi-
vidual observation period after the last PV ablation pro-
cedure irrespective of the number of PV ablations
combined for both groups, procedure duration, ablation
duration (deﬁned as time from the ﬁrst to the last ablation
point), RF current application duration, ﬂuoroscopy time,
and procedure-related complications. Procedure-related
complications were deﬁned as death, atrio-esophageal
ﬁstulae, pulmonary vein stenosis requiring interventions,
pericardial tamponade requiring drainage, systemic
embolic events, phrenic nerve paralysis, femoral vessel
damage requiring surgery, blood transfusion or prolonga-
tion of hospitalisation, and clinically and radiologically
veriﬁed infections.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation or as median with inter-quartile range if appro-
priate. Normally distributed data were compared using the
independent Student’s t test. Otherwise, comparisons
between groups were performed using the Mann–Whitney
U test. One-way ANOVA or Kruskal–Wallis ANOVA
(with Dunns post hoc test) were used to test for learning
curve effects. A Kaplan–Meier analysis with the log-rank
test was used to determine the probability of freedom from
recurrent AT/AF. All tests are two-tailed. A p value\0.05
is considered statistically signiﬁcant.
We expected a mean acute PV isolation rate of
3.5 ± 0.6 PVs per patient. Based on this assumption a
sample size of 100 RMN and 50 control patients would
allow detection of a difference in acute PV isolation of 0.3
PVs with 80% power and a two-tailed alpha of 5%.
Results
Patient characteristics
A total of 161 patients were included. Data from 107
patients in the RMN group and 54 patients in the CON
group were analysed. Patient baseline characteristics are
illustrated in Table 1 and were comparable between
groups. In both groups, about two-thirds of the patients
were in persistent AF, deﬁned as AF lasting[7 days or
requiring cardioversion according to current guidelines
[11]. The persistent AF cohort included three patients with
long-standing persistent AF (lasting for C1 year) in the
CON group and two in the RMN group. In both groups,
22% of the patients had a prior circumferential pulmonary
vein ablation before the index procedure.
Acute and long-term success
At the end of the index procedure 3.7 ± 0.8 PVs in the
CON group and 3.8 ± 0.7 PVs in the RMN group were
isolated (p = 0.34). Electrical isolation of all PVs was
achieved in 90% of the RMN-guided cases and in 87% of
the subjects in the CON group (p = 0.6).
By Kaplan–Meier analysis, the percentage of patients
who were free of any AT/AF episode at 12 months of
follow-up was 53.5% in the RMN group and 55.5% in the
CON group (p = 0.57, Fig. 1). As illustrated in Fig. 2, the
percentage of patients who were free of symptomatic AF
recurrence at 12 months of follow-up was 66.3% in the
RMN group and 62.1% in the CON group (p = 0.80).
Antiarrhythmic drugs were prescribed to 25% of the
patients without symptomatic AF recurrence in the CON
group (n = 32) and to 29% in the RMN group (n = 36).
Of those patients, 10% in the CON group and 11% in the
RMN group were on amiodarone.
In both the RMN and CON group, long-term success
rates (as deﬁned by freedom from AT/AF during follow-
up) tended to be higher in patients with a history of par-
oxysmal versus persistent AF (RMN: 66 vs. 49%; CON: 63
vs. 52%) and in patients with LA diameter B45 mm as
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vs. 47%) (Fig. 3).
Freedom from symptomatic AF combining both groups
after a follow-up duration of 382 ± 187 days and
1.5 ± 0.6 PV isolations (including PV isolations before
the index procedure) was 83%. Following the index
procedure, additional PV ablation procedures were con-
sidered only outside the blanking period and were per-
formed in 23% of the patients in the RMN group and in
24% of the patients in the CON group. A total of 40% of
these patients were on antiarrhythmic drugs at the end of
the respective observation period with 14% of the patients
being on amiodarone.
Procedural parameters and complications
As illustrated in Fig. 4, use of the RMN system was
associated with longer procedure duration (RMN:
225.5 ± 54.6 min, CON: 165.6 ± 52.4 min, p\0.0001),
longer ablation times (RMN: 125.3 ± 46.5 min, CON:
79.6 ± 28.5 min, p\0.0001) and longer RF current
application duration (RMN: 50.4 ± 17.7 min, CON:
Table 1 Patient Characteristics
AAD antiarrhythmic drugs, AF
atrial ﬁbrillation, LA left atrium,
LVEF left ventricular ejection
fraction
RMN (n = 107) CON (n = 54) P value
Gender (male/female) 66/41 34/20 ns
Age (years) 62 ± 10 61 ± 10 ns
Arterial hypertension 75 (70%) 40 (74%) ns
Coronary artery disease 24 (22%) 7 (13%) ns
Hypertensive heart disease 27 (25%) 7 (13%) ns
Other 19 (17%) 5 (11%) ns
Lone AF 14 (13%) 7 (13%) ns
LA size (mm) 47 ± 64 5 ± 7n s
LVEF (%) 55 ± 85 5 ± 8n s
Paroxysmal AF 34 (32%) 18 (33%) ns
Persistent AF 73 (68%) 36 (67%) ns
Prior AF ablation 23 (22%) 12 (22%) ns
Previous AADs 1.1 ± 0.8 1.4 ± 0.8 ns
Flecainide 54 (50%) 34 (63%) ns
Propafenone 12 (11%) 4 (6%) ns
Sotalol 14 (13%) 12 (22%) ns
Amiodarone 40 (37%) 19 (37%) ns
Fig. 1 Freedom from any AT/AF recurrence in the CON group
versus the RMN group. The Kaplan–Meier analysis during the ﬁrst
12 months of follow-up revealed no signiﬁcant difference between
the two groups
Fig. 2 Freedom from symptomatic AF recurrence in the CON group
versus the RMN group. The Kaplan–Meier analysis during the ﬁrst
12 months of follow-up revealed no signiﬁcant difference between
the two groups
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12343.9 ± 11.0 min, p\0.05) as compared to the CON
group. In contrast, ﬂuoroscopy time was lower in the RMN
[12 (9–17) min] than in the CON [37 (29–44) min] group
(p\0.0001). Furthermore, ﬂuoroscopy time signiﬁcantly
decreased in the RMN group over time (Fig. 5). No
learning curve effect was observed for the remaining pro-
cedural parameters (procedure duration, ablation time and
RF current application duration).
Major complications occurred in 6 of the 161 proce-
dures (3.7%), with no signiﬁcant difference between the 2
treatment groups (p = 0.75). One procedure-related
complication was observed in the CON group (aspiration
pneumonia). In the RMN group, procedure-related com-
plications were cardiac tamponade requiring pericardial
puncture (n = 2), hematoma after femoral vein puncture
requiring blood transfusion (n = 1) or prolonging hospital
stay (n = 1), and transient ischemic attack (n = 1).
Cardiac tamponades occurred subacutely, in one case
30 min after the end of an uneventful procedure, in the
other subject several hours after an uncomplicated
ablation.
Discussion
Main ﬁnding
The main ﬁnding of this prospective observational study is
that RMN-guided circumferential PV ablation with an
open-irrigated mapping and ablation catheter results in
comparable acute and long-term success and complication
rates as compared to the CON approach. Utilization of the
RMN system reduces ﬂuoroscopy time, but increases
ablation and total procedure times as compared to the CON
ablation technique.
Acute and long-term success
Manually guided RF ablation for PV isolation has emerged
as a standard second line treatment in patients with
symptomatic AF [1]. Nevertheless, efforts continue to
improve success rates and patient safety as well as proce-
dural efﬁcacy reducing procedure times and radiation
exposure to patients and operators.
Fig. 3 Freedom from any AT/AF recurrence dependent on type of
AF upon presentation for initial procedure (paroxysmal vs. persistent,
upper panels) and LA size (lower panels). In both the RMN (right
panels) and CON (left panels) group, long-term success rates tended
to be higher in patients with a history of paroxysmal AF than in
subjects with persistent AF and in patients with an LA diame-
ter B 45 mm as compared to LA[45 mm
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freedom from symptomatic AF or any AF/AT was
achieved in a comparable proportion of patients in the
RMN and the CON group. So far, only limited data are
available on the clinical utility of the RMN system for
catheter-based PV isolation [5–10]. Early reports used non-
irrigated ablation catheters, which limits the comparability
to our results [7, 8, 10]. Very recently, ﬁrst reports on the
efﬁcacy of RMN-guided PV isolation with an open-irri-
gated ablation catheter have been published by single
centers [5, 6, 9]. Chun et al. [6] evaluated the efﬁcacy of an
RMN-guided open-irrigated ablation catheter in a pre-
market design and compared it to the efﬁcacy of the
advanced, marked-released RMN catheter. With the cur-
rently available catheter, the group achieved isolation of all
PVs in 93% of the cases, and 70% of the patients remained
in sinus rhythm during a median follow-up of 18 months.
Arya et al. [5] report in their retrospective analysis com-
plete isolation of all PVs during RMN-guided PV ablation
with an open-irrigated catheter in 88% of the cases. Sixty-
one percent of the RMN patients as compared to 68% in the
conventional group remained free from AF after 6 months
of follow-up. The retrospective analysis by Miyazaki et al.
[9] demonstrated acute isolation of all 4 PVs in 87% of the
30 patients investigated with an RMN-guided open-irri-
gated catheter. At 12 months of follow-up after a single
procedure, 69% of the patients were free of AF recurrence
without antiarrhythmic drugs as compared to 62% in the
manual group.
In the present study, long-term freedom from symp-
tomatic AF was achieved in 83% of all patients with
1.5 ± 0.6 PV isolations. This data is in line with the
general success rate from a recent meta-analysis from
Cappato et al. [3], who reported that 85% of the patients
were free from symptomatic AF after a median of 1.4
procedures. The long-term freedom from any AT/AF after
a single procedure observed in our study is comparable to
recently published data by Wilber et al. [12]. However, a
meta-analysis by Calkins et al. [13] revealed a single
procedure success rate of 72% (on or off antiarrhythmic
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123medication). The lower procedure success rate in our
study as compared to this meta-analysis and the study by
Chun et al [6] and Miyazaki et al. [9] may have several
explanations. First, a larger proportion of patients in our
study had enlarged left atria or presented with persistent
AF. Several prior investigations as well as our own data
indicate that these factors may inﬂuence the success of
AF ablation [3, 14–16]. Second, we performed PV iso-
lation without additional ablation also in patients suffering
from persistent AF. In these subjects, PV isolation com-
bined with linear lesions (e.g., mitral isthmus line) and/or
ablation of complex fractionated electrograms may
increase the success rate of the procedure [17]. This may
potentially occur at the cost of an increased incidence of
atrial tachycardias [18, 19] and other procedural compli-
cations [2, 20]. At our institution, we therefore prefer an
approach to combine the effects of circumferential PV
isolation with antiarrhythmic medication as needed. This
concept can explain the higher proportion of patients on
antiarrhythmic drugs in our study but is supported by the
relatively low incidence of major complications. Third,
we veriﬁed electrical isolation of the PVs without the aid
of a circular mapping catheter. Although the use of a
circular mapping catheter is still considered as the gold
standard to ensure complete PV isolation, growing evi-
dence exists [21–23] that a single-catheter approach (as
utilized also in our study) may be equally effective for the
achievement and veriﬁcation of PV isolation [21, 22] and
for the prevention of AF recurrences during follow-up
[23]. We decided to apply the single-catheter approach for
mapping and ablation since the use of a manually guided
circular mapping catheter increases the complexity of the
procedure and contradicts the concept of remote
navigation.
Fluoroscopy time
The use of RMN in the present investigation was associ-
ated with considerably shorter ﬂuoroscopy times as com-
pared to the CON approach, despite longer ablation times.
In the RMN group ﬂuoroscopy time decreased signiﬁcantly
over the course of the study. This beneﬁt of RMN-guided
ablation has previously also been observed by our group
[24] and other investigators [6, 8, 25] in studies on different
arrhythmias including AF. The reduction in ﬂuoroscopy
time associated with RMN-guided ablation may be
explained by the fact that the risk of cardiac perforation is
rather low with the ﬂexible tip of the magnetic catheter tip
as compared to the stiff tip of a conventional ablation
catheter tip. Large catheter movements without frequent
ﬂuoroscopic visualization of the catheter tip can therefore
be made safely only with the ﬂexible tip of the RMN
ablation catheter. In this context, it appears noteworthy that
two cardiac tamponades occurred in the RMN group of our
study. The sub-acute time course of these complications
lets one speculate that repetitive ablation at the perforation
site rather than mechanical perforation of the LA wall
accounts for these complications. The RMN system may
increase catheter stability and thereby local lesion size
[25–27]. We therefore rigorously avoided prolonged
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the cases of sub-acute pericardial effusion.
RF current delivery
Our data indicate that more RF current has to be delivered
when utilizing RMN-guided ablation as compared to the
manual approach to achieve equally effective ablation
lesions. This ﬁnding is in line with prior reports that sug-
gest that RMN-guided ablation may produce less effective
linear lesions [7, 24] but may be at least equally effective
for focal ablation targets [25, 26]. The maximal endocar-
dial force exerted by the RMN-system to the magnetic
catheter tip is generally lower than that applied manually to
the conventional ablation catheter tip [28]. Given the
complex anatomy of the LA, one might assume that the tip-
to-tissue contact may be insufﬁcient to produce effective
ablation lesions with the RMN system in locations that are
difﬁcult to reach (e. g., right inferior PV) and/or at regions
with thicker myocardium (e.g., the ridge between left atrial
appendage and left superior PV). In return, exactly this
feature of RMN may be desirable for increasing safety of
the procedure. In this study, the magnetic ﬁeld strength
used was 0.08 Tesla. Since recently, the magnetic navi-
gation system can apply higher ﬁeld strengths of 0.1 Telsa,
which might enhance the effectiveness of the produced
lesions.
Procedure duration and ablation time
Longer ablation times with RMN-guided ablation also
translated into longer procedure times as compared to the
CON group of our study. These are not necessarily
explained by the longer RF application time, which
amounted to 7 min on average. In addition, the preparation
time before the start of mapping contributes in a minor
fashion as we demonstrated earlier for RMN-guided abla-
tion of typical atrial ﬂutter [24]. Rather an inherently
slower speed in navigation of the LA or other cardiac
chambers with RMN guided navigation as compared to
manual navigation is reﬂected. When considering the
numerous changes of catheter position necessary during the
procedure, small delays between the computerized demand
of vector direction change, movement of the permanent
magnets and the magnetic ﬁeld, and actual catheter
movement must add to longer procedure times with RMN-
guided circumferential PV isolation.
Limitations
The main limitation is the non-randomized design of our
study. Furthermore, inherent to AF studies asymptomatic
episodes of AF may have been missed.
Conclusion
RMN-guided circumferential PV ablation with an open-
irrigated catheter provides comparable acute and long-term
success rates as compared to manual catheter navigation.
Complication rates of the procedure are similar between
the two groups. The use of RMN is associated with
markedly reduced ﬂuoroscopy time, but prolonged ablation
and procedure duration.
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